# Apyx Medical Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Apyx Medical Corp). ## Overview Apyx Medical Corp designs, develops, manufactures, and sells electrosurgical equipment and medical devices, with a particular focus on its helium plasma technology platform. The company serves both OEM customers and physicians in the surgical aesthetics market, where it markets devices used in cosmetic and certain surgical procedures. Its product set has expanded from core generators and handpieces to newer systems such as the Apyx One Console and the Renuvion Micro Handpiece. Apyx also manufactures products for third-party medical device companies under OEM agreements, including a long-term supply arrangement with Symmetry Surgical. The business is centered in the United States but operates with international manufacturing and distribution support, including production in Bulgaria and sales outside the U.S. ## Products & services • Helium plasma energy systems and accessories • Renuvion handpieces and Micro Handpiece • Apyx One Console multi-energy generator • OEM manufacturing of electrosurgical devices • Medical device accessories and related components - **Surgical Aesthetics Systems** (55%) — Energy-based devices and consoles used by plastic, cosmetic, and related surgeons for soft tissue contraction and aesthetic procedures. - **OEM Manufacturing** (25%) — Generators, devices, and accessories produced for third-party medical device manufacturers under supply agreements. - **Handpieces and Consumables** (15%) — Single-use or procedure-linked handpieces and accessories used with the company's energy platforms. - **Other Specialty Surgical Products** (5%) — Opportunistic specialty products sold to niche medical device customers outside the core aesthetics focus. - Helium plasma energy systems and accessories - Renuvion handpieces and Micro Handpiece - Apyx One Console multi-energy generator - OEM manufacturing of electrosurgical devices - Medical device accessories and related components ## Customers Apyx sells primarily to physicians and surgeons in cosmetic and surgical aesthetics, especially plastic and cosmetic surgeons who buy capital equipment and procedure-specific handpieces to perform elective procedures. These customers are attracted by the clinical utility of the helium plasma platform, the ability to expand procedure offerings, and the support tools built into the Apyx One Console. The company also sells to large medical device manufacturers and smaller start-up companies through OEM agreements, where customers outsource design or manufacturing of electrosurgical products. Outside the U.S., the company reaches customers through an international distributor network, which broadens access to surgical aesthetics and selected oncology or specialty applications. Demand is influenced by discretionary spending, physician adoption, and the willingness of OEM partners to place purchase orders. - **Plastic and cosmetic surgeons** (primary) — Buy consoles, handpieces, and accessories for elective aesthetic procedures because the technology supports their practice mix and procedure economics. - **OEM medical device manufacturers** (primary) — Purchase generators, devices, and accessories under supply agreements to outsource production and access Apyx's electrosurgical expertise. - **Start-up medtech companies** (secondary) — Use Apyx for energy-based design and manufacturing support when they need a development partner with electrosurgical know-how. - **International distributor channel** (secondary) — Buys or resells products into non-U.S. markets to extend the reach of the surgical aesthetics platform. - Plastic and cosmetic surgeons buying systems for elective aesthetic procedures - Physicians seeking helium plasma tools for soft tissue contraction applications - Medical device OEM partners outsourcing electrosurgical product manufacturing - Start-up medtech companies needing energy-based design and production support - International distributors serving non-U.S. surgical aesthetics markets ## Geography Apyx is headquartered in the United States and manufactures most of its products in Clearwater, Florida, while also operating a manufacturing facility in Sofia, Bulgaria. The company uses a global distributor network to sell outside the U.S., and management has specifically noted expansion of helium plasma use in cosmetic surgery markets outside the United States and in surgical oncology markets. The Clearwater site is strategically important because it supports core production, but it is also exposed to hurricane risk and other weather disruptions. Bulgaria provides geographic redundancy and access to outsourced labor-intensive assembly and sterilization support, which helps diversify manufacturing risk. Because much of the business is tied to discretionary cosmetic procedures, regional economic conditions and physician adoption rates can materially affect demand. - United States is the core market for surgical aesthetics sales and OEM activity - Clearwater, Florida is a key manufacturing site and operational hub - Sofia, Bulgaria supports manufacturing and supply-chain redundancy - International distributors extend sales into non-U.S. markets - Outside-U.S. growth has included cosmetic surgery and surgical oncology uses - Florida weather exposure can disrupt production and customer fulfillment ## Strategy Apyx is prioritizing its Surgical Aesthetics segment, where management believes the market is larger and margins are more attractive than the OEM business. The company is investing in product launches, clinical support, and surgeon training to accelerate adoption of its helium plasma technology and expand the installed base. Recent launches such as the Apyx One Console and Renuvion Micro Handpiece show a strategy of broadening the platform with more versatile and user-friendly devices. At the same time, management expects OEM revenue to decline over time as resources are shifted toward aesthetics, although opportunistic specialty products may still be pursued. The strategy is to become a preferred or sole provider in cosmetic surgical equipment by combining product innovation, direct sales, and distributor reach. - **Grow Surgical Aesthetics adoption** (short-term) — This is the company's core growth engine and the segment management believes offers the best margin profile. - **Launch and refine new product platforms** (medium-term) — New devices expand use cases, improve usability, and help defend the platform against competing energy-based systems. - **Reduce reliance on OEM revenue** (medium-term) — Management expects OEM revenue to decline as the company reallocates resources to higher-value aesthetics opportunities. - Shift commercial focus toward Surgical Aesthetics because it offers better growth and margins - Expand the installed base of helium plasma technology through new product launches - Use clinical support and surgeon training to improve adoption and outcomes - Broaden the platform with multi-energy and smaller-profile handpiece options - Maintain OEM relationships while allowing that segment to decline over time - Leverage direct sales plus distributors to widen market reach ## Risks Apyx faces demand risk because a large part of its business depends on discretionary cosmetic and aesthetic procedures, which can weaken when consumer confidence, credit conditions, or physician capital spending deteriorate. The company also depends on regulatory clearances for new products and expanded indications, so delays or denials can slow commercialization and reduce the return on R&D spending. Supply-chain concentration is another material risk because many raw materials are single-sourced and some components and services are outsourced, making the business vulnerable to disruptions, lead-time issues, and cost inflation. Manufacturing concentration in Clearwater, Florida creates weather and hurricane exposure, while the Bulgaria facility adds cross-border operational complexity. OEM revenue is also exposed to customer ordering behavior because partners are not obligated to buy after development, which can make revenue less predictable. - **Weak discretionary demand for cosmetic and aesthetic procedures** [high] — The core Surgical Aesthetics business depends on elective spending by patients and physician purchasing decisions, which are sensitive to macro conditions. - **Regulatory clearance or approval delays** [high] — New products and expanded indications require regulatory success before commercialization, so delays can defer revenue and increase development expense. - **Supply-chain disruption and single-source dependence** [high] — The company relies on outsourced components and single-source suppliers, which can interrupt manufacturing and customer fulfillment. - **Hurricane and weather disruption in Clearwater, Florida** [medium] — A key manufacturing facility is located in a weather-exposed region, creating operational and inventory risk. - **OEM customer order volatility** [medium] — OEM customers have no legal obligation to continue purchasing after development, making this revenue stream less durable. - Discretionary cosmetic demand can fall in weak economies or tight credit markets - Regulatory clearance delays can block new product launches or expanded indications - Single-source suppliers and outsourced components create supply-chain fragility - Hurricane exposure at Clearwater can interrupt production and shipments - OEM customers are not obligated to place future orders after development - Higher inflation and interest rates can pressure customer spending and costs ## Accounting Apyx's revenue profile is affected by the mix between OEM supply arrangements and direct sales of surgical aesthetics products, which can create different timing and margin patterns across periods. OEM revenue tied to manufacturing and supply agreements may depend on customer purchase orders and agreed pricing, while direct device sales can be more sensitive to shipment timing and physician adoption. The company also faces judgmental accounting around inventory, outsourced manufacturing commitments, and potential obsolescence as it launches new product generations and phases out older offerings. Because the business has recurring net losses and may need additional capital, investors should also watch financing-related accounting and dilution effects, including the impact of equity offerings on per-share metrics. Seasonal or quarter-to-quarter fluctuations can occur as capital equipment purchases, procedure volumes, and launch timing shift across reporting periods. - **Revenue recognition by business line** — Can shift reported revenue and gross margin timing - **Inventory valuation and obsolescence** — Can affect cost of sales and operating results - **Equity financing and dilution** — Impacts EPS and capital structure analysis - **Going-concern and liquidity assumptions** — Important for solvency and valuation assessment - Revenue timing differs between OEM supply contracts and direct device sales - Purchase-order based OEM activity can create quarter-to-quarter volatility - Inventory valuation matters as new products replace older handpieces and consoles - Outsourced manufacturing and commitments can affect cost recognition and margins - Equity financing and share issuance can dilute per-share results - Loss history and capital needs increase scrutiny of going-concern and financing assumptions --- *Last updated: 2026-08-11T04:46:21.185101+00:00*